Bladder Cancer

Pembrolizumab As Second-Line Tx for Urothelial Cancer Ups Survival

Pembrolizumab As Second-Line Tx for Urothelial Cancer Ups Survival

By

Use of the monoclonal antibody was associated with a 27% lower risk of death versus chemotherapy.

Pre-Cystectomy Chemo Does Not Up Survival in 'Real World' Setting

Pre-Cystectomy Chemo Does Not Up Survival in 'Real World' Setting

By

Finding contrasts with results of randomized clinical trials.

Bladder Surgery Complications Predicted by New Model

Bladder Surgery Complications Predicted by New Model

By

Nomograms specific to radical cystectomy currently do not exist to aid stratification of a patient's risks for complications.

Adjuvant Radiation Therapy Common in MIBC

Adjuvant Radiation Therapy Common in MIBC

By

Survey finds that 46% of radiation oncologists have administered ART to patients with muscle-invasive bladder cancer on at least one occasion.

Post-Radical Cystectomy Survival Outcomes Predicted by Preop NLR

Post-Radical Cystectomy Survival Outcomes Predicted by Preop NLR

By

A neutrophil-to-lymphocyte ratio below 3.09 is associated with significantly longer overall and disease-specific survival.

Nivolumab Approved for Refractory Urothelial Carcinoma

Nivolumab Approved for Refractory Urothelial Carcinoma

By

The drug is indicated for treating patients with locally advanced or metastatic disease that progresses despite platinum-containing chemotherapy.

Androgen Suppression May Prevent Intravesical Recurrence of NMIBC

Androgen Suppression May Prevent Intravesical Recurrence of NMIBC

During a median followup of 3.6 and 3.0 years intravesical recurrence developed in 4 (12.5%) and 59 men (30.1%) with and without androgen suppression therapy, respectively.

Significant Prostate Cancer Found in Advanced Bladder Cancer Patients

Significant Prostate Cancer Found in Advanced Bladder Cancer Patients

By

In a study, 53.1% of patients had concomitant prostate cancer in radical cystectomy specimens.

ASS1 Enzyme Loss Occurs in Invasive Bladder Cancer

ASS1 Enzyme Loss Occurs in Invasive Bladder Cancer

ASS1 loss occurs in invasive bladder cancer and is targetable by ADI-PEG 20.

Bladder Cancer-Pioglitazone Link Reasserted by FDA

Bladder Cancer-Pioglitazone Link Reasserted by FDA

By

After analyzing new data, the FDA again warns that the diabetes drug may be associated with an increased risk for bladder cancer.

Thromboembolic Events Common With Neoadjuvant Chemo for MIBC

Thromboembolic Events Common With Neoadjuvant Chemo for MIBC

Before and after radical cystectomy, thromboembolic events are common in bladder cancer patients who undergo neoadjuvant chemotherapy.

Low Vitamin D Linked to Bladder Cancer

Low Vitamin D Linked to Bladder Cancer

Low levels of vitamin D in the blood may prevent the cells within the bladder from stimulating an adequate response to abnormal cells.

Tumor Features Predict Post-Cystectomy Recurrence

Tumor Features Predict Post-Cystectomy Recurrence

Predictors of distant recurrences after robot-assisted radical cystectomy were mainly dictated by pathological tumor characteristics.

Nivolumab Shows Promise for Metastatic Urothelial Cancer

Nivolumab Shows Promise for Metastatic Urothelial Cancer

By

Based on a small study, investigators report encouraging efficacy and safety.

Bladder Cancer Progression Linked to Collagen Changes

Bladder Cancer Progression Linked to Collagen Changes

By

Increased type I collagen mRNA expression in the extracellular matrix microenvironment is associated with poor progression-free survival.

Infection Occurs in One Fourth of Radical Cystectomy Patients

Infection Occurs in One Fourth of Radical Cystectomy Patients

By

Patients who underwent a radical cystectomy (RC) developed postoperative infection after a median of 13 days.

Tight Glycemic Control May Help Diabetic NMIBC Patients

Tight Glycemic Control May Help Diabetic NMIBC Patients

By

Patients with diabetes had a significant 42% increased risk of recurrence of cancer and 79% increased risk of progression.

BCG Alone for Bladder CIS Offers Better Long-Term Outcomes

BCG Alone for Bladder CIS Offers Better Long-Term Outcomes

By

This approach is associated with a 26% decreased risk of disease recurrence at 15 years compared with alternating therapy with mitomycin C.

Tumor Site in Bladder Adenocarcinoma Predicts Survival Outcomes

Tumor Site in Bladder Adenocarcinoma Predicts Survival Outcomes

By

Tumors in the dome or urachus confer a better prognosis than those in the lateral wall and base, study finds.

Bladder Cancer Urine Test Accurate

Bladder Cancer Urine Test Accurate

By

Assay could cut down on cystoscopies, researchers say.

8% of Cancer Patients Develop a Second Malignancy

8% of Cancer Patients Develop a Second Malignancy

Second cancer was fatal in 55% of the cases studied.

Metformin May Have a Protective Effect in Bladder Cancer Patients

Metformin May Have a Protective Effect in Bladder Cancer Patients

By

Diabetics taking the drug had a significant 68% decreased risk of grade progression compared with diabetics not on the drug.

New Study Supports Use of Trimodal Therapy for MIBC

New Study Supports Use of Trimodal Therapy for MIBC

By

Researchers find no difference in 5-year disease-specific survival between multi-disciplinary bladder-sparing approach and radical cystectomy.

Early Recurrence After Laparoscopic Radical Cystectomy Explored

Early Recurrence After Laparoscopic Radical Cystectomy Explored

During first 24 months, 8.7% of patients with favorable pathological characteristics had progressed.

Gender Differences in Chemotherapy for Stage IV Bladder Cancer

Gender Differences in Chemotherapy for Stage IV Bladder Cancer

Women with stage IV bladder cancer have a lower median overall survival rate when compared to men.

Immunotherapy Helps Advanced Bladder Cancer Patients

Immunotherapy Helps Advanced Bladder Cancer Patients

About a quarter of older patients deemed too frail for chemo responded to atezolizumab.

Achieving 4 Lifestyle Standards May Reduce Cancer Mortality

Achieving 4 Lifestyle Standards May Reduce Cancer Mortality

Four key lifestyle factors include weight, exercise, no smoking, and limiting alcohol.

Drug Cleared for Refractory Advanced Bladder Cancer

Drug Cleared for Refractory Advanced Bladder Cancer

By

Atezolizumab received accelerated FDA approval for patients whose disease has progressed despite platinum-based chemotherapy.

Leisure Activity Linked With Lower Risk of Several Cancers

Leisure Activity Linked With Lower Risk of Several Cancers

Findings for self-reported leisure-time physical activity of moderate to vigorous intensity.

Prostate, Bladder Cancer Linked to BPH

Prostate, Bladder Cancer Linked to BPH

By

In a meta-analysis, men with benign prostatic hyperplasia had a 2.9 times and 1.7 times increased incidence of prostate cancer and bladder cancer, respectively.

Sign Up for Free e-newsletters